We Help Companies Find New Sales Opportunities
Skyepharma is to sell its injectable drugs business to Blue Acquisition for up to £42m, in order to focus on its Flutiform asthma treatment, and has also announced plans to raise £15m in a share placing.
Skyepharma is planning to relocate its London headquarters from Piccadilly to a less expensive area, in order to cut costs.
Skyepharma is to raise £35m in a rights issue to fund the development of its Flutiform asthma drug.
Skyepharma has invested £2.5m in Micap of Newton-le-Willows, in order to investigate the pharmaceutical applications of Micap's micro-encapsulation technology.
Skyepharma is to raise £60m through a convertible bond in order to fund the development of its own drugs, having decided to change its strategy away from developing products for other companies.
Skyepharma is forming a joint venture with PA Consulting to develop a new asthma inhaler.
Skyepharma is acquiring Hyal Pharmaceutical Corporation of Canada for £3.8m.
Skyepharma plans to raise £140m on the market to acquire Jago Holdings, the Swiss drug delivery concern.